Jong Chul Won

3.8k total citations
83 papers, 3.0k citations indexed

About

Jong Chul Won is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Physiology. According to data from OpenAlex, Jong Chul Won has authored 83 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Endocrinology, Diabetes and Metabolism, 30 papers in Molecular Biology and 27 papers in Physiology. Recurrent topics in Jong Chul Won's work include Metabolism, Diabetes, and Cancer (20 papers), Diabetes Treatment and Management (18 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (12 papers). Jong Chul Won is often cited by papers focused on Metabolism, Diabetes, and Cancer (20 papers), Diabetes Treatment and Management (18 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (12 papers). Jong Chul Won collaborates with scholars based in South Korea, United States and Puerto Rico. Jong Chul Won's co-authors include Joong‐Yeol Park, Eun Hee Koh, Ki‐Up Lee, Kyung Soo Ko, Hyuk‐Sang Kwon, Min‐Seon Kim, Min-Seon Kim, Tae Sun Park, Dae Jung Kim and Kee‐Ho Song and has published in prestigious journals such as Nature Neuroscience, PLoS ONE and Diabetes Care.

In The Last Decade

Jong Chul Won

78 papers receiving 2.9k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Jong Chul Won 1.1k 891 838 508 403 83 3.0k
Eun Hee Koh 1.2k 1.1× 1.3k 1.4× 464 0.6× 791 1.6× 524 1.3× 77 3.1k
Annalisa Natalicchio 1.1k 1.1× 1.4k 1.6× 996 1.2× 628 1.2× 645 1.6× 77 4.0k
Ichiro Wakabayashi 743 0.7× 778 0.9× 983 1.2× 761 1.5× 405 1.0× 271 3.8k
Francis Kim 1.3k 1.2× 1.1k 1.2× 463 0.6× 1.2k 2.3× 625 1.6× 79 5.0k
Jorge Calles-Escandón 1.7k 1.6× 1.1k 1.2× 1.1k 1.3× 438 0.9× 536 1.3× 81 4.4k
León Ferder 1.0k 1.0× 1.2k 1.4× 885 1.1× 420 0.8× 378 0.9× 105 4.8k
Milan Obradović 590 0.6× 590 0.7× 441 0.5× 493 1.0× 324 0.8× 78 2.4k
Sebastio Perrini 1.5k 1.4× 1.7k 1.9× 1.1k 1.3× 712 1.4× 710 1.8× 87 4.6k
James Brown 954 0.9× 954 1.1× 678 0.8× 739 1.5× 396 1.0× 59 3.3k
Takuro Okamura 1.2k 1.1× 513 0.6× 609 0.7× 512 1.0× 264 0.7× 126 2.6k

Countries citing papers authored by Jong Chul Won

Since Specialization
Citations

This map shows the geographic impact of Jong Chul Won's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jong Chul Won with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jong Chul Won more than expected).

Fields of papers citing papers by Jong Chul Won

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jong Chul Won. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jong Chul Won. The network helps show where Jong Chul Won may publish in the future.

Co-authorship network of co-authors of Jong Chul Won

This figure shows the co-authorship network connecting the top 25 collaborators of Jong Chul Won. A scholar is included among the top collaborators of Jong Chul Won based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jong Chul Won. Jong Chul Won is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kim, Chong Hwa, Jae‐Seung Yun, Jong Chul Won, et al.. (2025). Clinical Characteristics and Epidemiology of Cardiovascular Autonomic Neuropathy in Peoples With Long-Standing Diabetes. Journal of Korean Medical Science. 40(28). e154–e154.
2.
Kim, Byung Gyu, et al.. (2025). Molecular Pathways in Diabetic Cardiomyopathy and the Role of Anti-hyperglycemic Drugs Beyond Their Glucose Lowering Effect. Journal of Lipid and Atherosclerosis. 14(1). 54–54.
3.
Kim, Nam Hoon, Soo Lim, In‐Kyung Jeong, et al.. (2025). Study Design and Protocol for a Randomized Controlled Trial of Enavogliflozin to Evaluate Cardiorenal Outcomes in Type 2 Diabetes (ENVELOP). Diabetes & Metabolism Journal. 49(2). 225–234. 1 indexed citations
4.
Kwak, Soo Heon, Kyung Ah Han, Eun Sook Kim, et al.. (2024). Long‐term efficacy and safety of enavogliflozin in Korean people with type 2 diabetes: A 52‐week extension of a Phase 3 randomized controlled trial. Diabetes Obesity and Metabolism. 26(10). 4203–4212. 1 indexed citations
5.
Han, Kyung Ah, You‐Cheol Hwang, Shinje Moon, et al.. (2024). Dual add‐on therapy of gemigliptin and dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin alone: The SOLUTION 2 study. Diabetes Obesity and Metabolism. 26(9). 3743–3752. 1 indexed citations
6.
7.
8.
Jin, Eun‐Sun, Jee‐Seon Shim, Sung Eun Kim, et al.. (2023). Dyslipidemia Fact Sheet in South Korea, 2022. Diabetes & Metabolism Journal. 47(5). 632–642. 22 indexed citations
9.
Jin, Eun‐Sun, Jee‐Seon Shim, Sung Eun Kim, et al.. (2023). Dyslipidemia Fact Sheet in South Korea, 2022. Journal of Lipid and Atherosclerosis. 12(3). 237–237. 24 indexed citations
10.
Kwak, Soo Heon, Kyung Ah Han, Kyung‐Soo Kim, et al.. (2023). Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24‐week, multicentre, randomized, double‐blind, placebo‐controlled, phase III trial. Diabetes Obesity and Metabolism. 25(7). 1865–1873. 17 indexed citations
11.
Won, Jong Chul. (2023). Paradigm Shift in Management of Hyperglycemia in Patients with Type 2 Diabetes: Glucocentric versus Organ Protection. Journal of Korean Diabetes. 24(2). 59–65. 1 indexed citations
12.
13.
Kim, Bo‐Yeon, Hyuk‐Sang Kwon, Suk Kyeong Kim, et al.. (2022). A Real-World Study of Long-Term Safety and Efficacy of Lobeglitazone in Korean Patients with Type 2 Diabetes Mellitus. Diabetes & Metabolism Journal. 46(6). 855–865. 8 indexed citations
14.
Bae, Ji Cheol, Soo Heon Kwak, Hyun Jin Kim, et al.. (2021). Effects of Teneligliptin on HbA1c levels, Continuous Glucose Monitoring-Derived Time in Range and Glycemic Variability in Elderly Patients with T2DM (TEDDY Study). Diabetes & Metabolism Journal. 46(1). 81–92. 9 indexed citations
15.
Kwak, Soo Heon, You‐Cheol Hwang, Jong Chul Won, et al.. (2019). Comparison of the effects of gemigliptin and dapagliflozin on glycaemic variability in type 2 diabetes: A randomized, open‐label, active‐controlled, 12‐week study (STABLE II study). Diabetes Obesity and Metabolism. 22(2). 173–181. 16 indexed citations
16.
Kim, Shin-Hye, et al.. (2018). Percentage fractions of urinary di(2-ethylhexyl) phthalate metabolites: Association with obesity and insulin resistance in Korean girls. PLoS ONE. 13(11). e0208081–e0208081. 22 indexed citations
17.
Won, Jong Chul, Jae Won Hong, Jung Hyun Noh, & Dong‐Jun Kim. (2016). Association Between Estimated 24-h Urinary Sodium Excretion and Metabolic Syndrome in Korean Adults. Medicine. 95(15). e3153–e3153. 14 indexed citations
18.
Kim, Tae Nyun, Jong Chul Won, Sojeong Lee, et al.. (2012). A decision tree-based approach for identifying urban-rural differences in metabolic syndrome risk factors in the adult Korean population.. PubMed. 35(9). 847–52. 15 indexed citations
19.
Won, Jong Chul, et al.. (2012). Prevalence and clinical characteristics of diabetic peripheral neuropathy in hospital patients with Type 2 diabetes in Korea. Diabetic Medicine. 29(9). e290–6. 74 indexed citations
20.
Han, Jeong Hee, Jong Chul Won, Choong Gon Choi, et al.. (2002). Diagnostic adequacy of ultrasound-guided fine needle aspiration in thyroid nodules. The Korean Journal of Internal Medicine. 62(4). 430–435. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eun Hee Koh Breakdown of academic impact, for papers by Annalisa Natalicchio Breakdown of academic impact, for papers by Ichiro Wakabayashi Breakdown of academic impact, for papers by Francis Kim Breakdown of academic impact, for papers by Jorge Calles-Escandón Breakdown of academic impact, for papers by León Ferder Breakdown of academic impact, for papers by Milan Obradović Breakdown of academic impact, for papers by Sebastio Perrini Breakdown of academic impact, for papers by James Brown Breakdown of academic impact, for papers by Takuro Okamura
Rankless by CCL
2026